Ocular Therapeutix (OCUL) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
November 8, 2021 4:01 PM ESTDEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $11.9 Million, Representing Year-Over-Year Growth of 120%
FDA Approved Supplemental New Drug Application (sNDA) for DEXTENZA for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
DEXTENZA Will Be Paid Through the End of 2022 and is Eligible for Separate Payment in the Ambulatory Surgery Center Beyond 2022
Conference Call to Discuss Third Quarter Results to be Held at 4:30 p.m. ET
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:... More
